$PIII

Short Interest in P3 Health Partners Inc. (NASDAQ:PIII) Rises By 293.3%

P3 Health Partners (NASDAQ:PIII) reported short interest of 283,541 shares as of May 15, up 293.3% from 72,094 on April 30; about 4.8% of shares are sold short, with a days-to-cover ratio near 0.0. The stock fell 26% on Friday to $12.18. UBS and Lake Street set $14 targets; TD Cowen reiterated hold. The company reported Q1 EPS of $0.32 on revenue of $386.39M.

Original reporting
Published May 31, 2026, 12:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 31, 2026, 1:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Short Interest in P3 Health Partners Inc. (NASDAQ:PIII) Rises By 293.3% — source image
Decision brief

The 30-second read

$PIIINeutralMed
01

Why it matters

A large short-interest increase can amplify price moves via forced covering, especially after an earnings beat. But without new guidance or contract/regulatory catalysts, the move may fade if fundamentals don’t follow through.

02

Market read

Traders may treat this as a positioning-driven volatility setup around a recently reported earnings beat and shifting sell-side targets.

03

What to watch

Days-to-cover is reported as 0.0 despite high average volume, suggesting the metric may be distorted by the article’s data handling; traders should verify the latest cover days and current borrow availability.

Relevance 8/10Novelty 6/10Timing: Positioning/volatility signal immediately after May short-interest update (as of May 15).

Background

The article is a short-interest and post-earnings recap for P3 Health Partners, including analyst target/ratings changes and a 13F institutional buy.

Company-level read

Ticker impact

$PIIINeutralMedium confidence
Context

Article reports P3 Health Partners’ short interest jumped 293.3% in May and highlights recent earnings beat plus analyst target changes.

Expected impact

Elevated volatility; potential short-covering pop if price holds above recent support, but risk remains given heavy short positioning and small market cap.

Evidence & confidence

The piece provides a concrete short-interest datapoint (293.3% rise; 4.8% short) and a recent earnings beat (May 14). However, it lacks forward guidance or new operational catalysts beyond analyst target updates.

Market effects

Healthcare analytics/software names may see read-across from short-interest-driven volatility rather than fundamentals.

Primarily US small/mid-cap sentiment; limited broader regional spillover implied.

Low—single-company microstructure/positioning story.

Counterpoint

Short-interest can rise for reasons unrelated to a near-term squeeze (e.g., persistent fundamental skepticism); the stock’s downtrend may dominate.

Key entities

  • P3 Health Partners Inc.

    Subject of the article; short interest rose 293.3% in May and it reported an EPS beat on May 14.

  • Lido Advisors LLC

    Bought 10,748 shares in Q1 per a 13F filing; owns ~0.15% at quarter-end.

Related articles

$PIIIHigh

P3 Health Partners Inc. (PIII): Results of Operations and Financial Condition

P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 piii-20260810xexx991.htm EX-99.1 Document Exhibit 99.1 P3 Health Partners Announces Second Quarter 2026 Results Raises Full-Year 2026 Adjusted EBITDA Guidance Management to Host Conference Call and Webcast August 10, 2026 at 4:30 PM ET HENDERSON, NV—August 10, 2026—P3 H

$QTTBMedAI 9/10

Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX

Biotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).

$FOURMed

Why Shift4 (FOUR) Stock Is Trading Lower Today

Shift4 Payments (NYSE:FOUR) shares fell about 6.4% after the company cut its 2026 outlook. Shift4 cited Middle East travel disruption, FX headwinds, and higher interest expense, lowering Gross Revenue less Network Fees guidance by about 200 bps and non-GAAP EPS to $5.15–$5.35 from $5.50–$5.70. Analysts at Raymond James and UBS trimmed price targets.

$AAPLMed

anniversary iPhone redesign reportedly remains on track

Bloomberg reports Apple’s rumored all-glass iPhone redesign for the 20th anniversary is still on track for next year’s iPhone Pro models, using new glass on the front and back and curving to the sides, with a metal band in the middle. This conflicts with Jefferies, which earlier said supply-chain checks indicated the all-glass plan was canceled. Jefferies downgraded AAPL and cut its price target to $263.66 from $285.56.

$AAPLMed

Apple Downgraded Again as iPhone Price Ceiling Hits

Jefferies downgraded Apple (AAPL) to underperform, citing limited options to raise iPhone average selling prices without hurting demand. The firm said Apple canceled a planned all-glass iPhone, leaving the foldable as the main driver of higher ASP and margins, though component costs could make it niche. Apple shares fell after the move and closed at $313.33 Friday.

$OKLOMed

Is Oklo a Millionaire Maker, or Is the Hype Overdone?

Oklo reported its first quarterly revenue for the quarter ended Aug. 7, generating $1.21 million versus none a year earlier, alongside a wider-than-expected net loss of about $48.5 million and operating expenses of about $74 million. The company said it has $3 billion in total liquidity and that its Groves Reactor reached first criticality. Oklo shares were up about 14% on the news.